Extended indication Treatment of locally advanced unresectable, metastatic or recurrent non-small cell lung cancer (NSCL
Therapeutic value No judgement
Total cost 22,050,000.00
Registration phase Withdrawn

Product

Registration

Therapeutic value

Expected patient volume per year

Expected cost per patient per year

Potential total cost per year

Off label use

Indication extension

Other information